Home / Therapeutic Area / The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)

The US Chronic Pain Market - Focus on Opioids: Trends & Opportunities (2014-2019)

Published: Nov 2014 | No Of Pages: 67 | Published By: Daedal Research
Scope of the report
 
The report titled “The US Chronic Pain Therapy Market: Trends & Opportunities (2014-2019)” provides an in-depth analysis of the United States chronic pain therapy market (including medication, surgeries and therapies) with detailed analysis of market sizing and growth and market share of the various drugs involved in the treatment of chronic pain. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall chronic pain therapy market has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Zogenix Inc., Egalet Corporation and NektarTheropeutics are profiled.
 
Segment Coverage
 
  • Oxycodone
  • Hydrocodone
  • Morphine
  • Hydromorphone
  • Fentanyl
  • Dihydrocodeine
  • Methadone
 
Company Coverage
 
  • Zogenix Inc.
  • Egalet Corporation
  • NektarTheropeutics
 
Executive Summary 
 
Chronic pain, defined as pain that lasts longer than six months and about 100 million Americans suffer from chronic pain that could be mild or agonizing, episodic or continuous, merely inconvenient or totally incapacitating.
 
The US chronic pain therapy market is expected to experience slow pace of growth in the near future. The major opioids used for medication in chronic pain are Oxycodone, Hydrocodone, Fentanyl, Methadone, Morphine, Hydromorphone and Dihydrocodeine. Compared to other opioids, hydrocodone products, the most commonly prescribed opioid and the most commonly prescribed pharmaceutical products in the United States, are growing at a substantial pace in the overall chronic pain therapy market. In the oxycodone business domain, the expected launch of Egalet 002 in the second quarter of 2015 by the leading player Egalet will change the dynamics of this domain as currently Oxycotin dominates the oxycodone market.
1. Executive summary    
 
2. Introduction: Chronic Pain    
 
3. The US Chronic Pain Therapy Market
3.1 Opioid Sales in US Chronic Pain Market: Sizing & Growth    
3.2 Opioid Sales in US Chronic Pain Market - Forecast: Sizing & Growth    
 
4. The US Chronic Pain Therapy Market: Segment Analysis
4.1 The US Oxycodone Market: Size and Growth    
4.2 The US Methadone Market: Size and Growth    
4.3 The US Morphine Market: Size and Growth    
4.4 The US Hydromorphone Market: Size and Growth
4.5 The US Hydrocodone Market: Size and Growth    
4.6 The US Dihydrocodeine Market: Size and Growth
4.7 The US Fentanyl Market: Size and Growth
    
5. The US Chronic Pain Therapy: Market Share Analysis    
 
6. Growth Drivers and Challenges:The US Chronic Pain Therapy Market
6.1 Growth Drivers
6.1.1 Rising Healthcare Expenditures    
6.1.2 Rise in Aging Demographics    
6.1.3 Economic Development
6.2 Market Challenges    
 
7. The US Chronic Pain Therapy Market Trends
7.1 Increasing number of Drug Approvals    
7.2 Incidence of pain conditions in the US households    
 
8. Competitive Landscape:The US Chronic Pain Therapy Market    
 
9. Company Profiles:The US Chronic Pain Therapy Market
9.1 ZogenixInc
9.1.1 Business Overview    
9.1.2 Financial Overview    
9.1.3 Business Strategies
9.2 Egalet Corporation
9.2.1 Business Overview
9.2.2 Financial overview    
9.2.3 Business Strategies
9.3 NektarTheropeutics
9.3.1 Business Overview    
9.3.2 Financial overview    
9.3.3 Business Strategies
Table 1: Types of Acute and Chronic pain
Table 2: WHO Guidelines for Pain Therapy
Table 3: Leading Players of US Chronic Pain Therapy Market    
Table 4: US Chronic Pain Therapy Market: Key Players and their product areas    
Table 5: Long Acting Morphine: Competition and Market Share    
Table 6: US Chronic Pain Therapy Market: Sales of Leading Companies    
Table 7: Products offered by Egalet    
Figure 1: US Opioid Sales in Chronic Pain Therapy Market: 2009-2013 (in US$ billions)    
Figure 2: US Opioid Sales in Chronic Pain Therapy Market - Forecast: 2014F-2019F (US$ B)    
Figure 3: US Oxycodone Market: by value- 2009-2013 (in US$ billion)    
Figure 4: Oxycodone Market: Share of Leading Players (2027)    
Figure 5: US Oxycodone Market: By value – Forecast: 2014F-2019F (in US$ billion)    
Figure 6: US Methadone Market: by Value- 2009-13 (in US$ million)    
Figure 7: US Methadone Market: By value – Forecast: 2014F-2019F (in US$ million)    
Figure 8: US Morphine Market: by value- 2009-13 (in US$ million)    
Figure 9: US Morphine Market: By value – Forecast: 2014F-2019F (in US$ million)    
Figure 10: US Long- Acting Morphine Market: 2014    
Figure 11: US Hydromorphone Market: by Value- 2009-13 (in US$ million)    
Figure 12: US Hydromorphone Market: By value – Forecast: 2014F-2019F (in US$ million)    
Figure 13: US Hydrocodone Market: by Value- 2009-13 (in US$ billion)    
Figure 14: US Hydrocodone Market: By value – Forecast: 2014F-19F (in US$ billion)    
Figure 15: US Dihydrocodeine Market: by Value- 2009-13 (in US$ billion)    
Figure 16: US Dihydrocodeine Market: By value – Forecast: 2014F-19F (in US$ billion)    
Figure 17: US Fentanyl Market: by value- 2009-13 (in US$ million)    
Figure 18: US Fentanyl Market: By value – Forecast: - 2014F-19F (in US$ million)    
Figure 19: The US Chronic Pain Therapy Market: Share of Opioids, 2013    
Figure 20: US Healthcare Expenditures per Capita, 2007-2013E (in US$)    
Figure 21: Growth of the US Aging population, 60 years and above as a percentage of total population, 2007-13E (in%)    
Figure 22: US GDP, 2007-13E (in Current US$ trillions)    
Figure 23: Number of Drugs Approval by FDA, 2000-2009    
Figure 24: Incidence of Pain in the US (in%)    
Figure 25: Percentage share of Long Acting Morphine – Value (in %)    
Figure 26: Zogenix Inc. Product Revenue, FY 2011-13 (in US$ million)    
Figure 27: Zogenix Inc. R&D Expenditure, FY 2011-13 (in US$ million)    
Figure 28: Egalet Revenue, FY 2011-13 (in US$ millions)    
Figure 29: Egalet R&D Expenditure, FY 2011-12 (in US$ million)    
Figure 30: Nektar Product Revenue, FY 2011-13 (in US$ million)    
Figure 31: Nektar R&D Expenditure, FY 2011-13 (in US$ million)  

 

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +